Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma

Journal of Veterinary Internal Medicine

Volumn 21, Issue 1, 2007, Pages 113-120

  U'Ren, Lance W ^a   Biller, Barbara J ^a   Elmslie, Robyn E ^b   Thamm, Douglas H ^a   Dow, Steven W ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b Veterinary Referral Center of Colorado   (United States)

Author keywords

Adjuvant; Allergenic; Cancer; Immunize; Liposome; Neoplasia; Vaccination

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; DOXORUBICIN;

ADJUVANT CHEMOTHERAPY; ANGIOSARCOMA; ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; DOG; DOG DISEASE; DRUG COMBINATION; HEART TUMOR; KIDNEY TUMOR; PHASE 1 CLINICAL TRIAL; SKIN TUMOR; SPLEEN TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CHEMOTHERAPY, ADJUVANT; DOG DISEASES; DOGS; DOXORUBICIN; DRUG THERAPY, COMBINATION; HEART NEOPLASMS; HEMANGIOSARCOMA; KIDNEY NEOPLASMS; SKIN NEOPLASMS; SPLENIC NEOPLASMS;

ANIMALIA; CANIS FAMILIARIS;

EID: 33847053266     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2007)21[113:EOANTV]2.0.CO;2     Document Type: Article

References (44)

1. Brown NO, Patnaik AK, MacEwen EG. Canine hemangiosarcoma: retrospective analysis of 104 cases. J Am Vet Med Assoc 1985;186:56-58.
2. Augustin-Voss HG, Smith CA, Lewis RM. Phenotypic characterization of normal and neoplastic canine endothelial cells by lectin histochemistry. Vet Pathol 1990;27:103-109.
3. Fosmire SP, Dickerson EB, Scott AM, et al. Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium. Lab Invest 2004;84:562-572.
4. Smith AN. Hemangiosarcoma in dogs and cats. Vet Clin North Am Small Anim Pract 2003;33:533-552, vi.
5. Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 2000;18:781-792.
6. Hammer AS, Couto CG, Swardson C, et al. Hemostatic abnormalities in dogs with hemangiosarcoma. J Vet Intern Med 1991;5:11-14.
7. Hargis AM, Feldman BF. Evaluation of hemostatic defects secondary to vascular tumors in dogs: 11 cases (1983-1988). J Am Vet Med Assoc 1991;198:891-894.
8. Maruyama H, Miura T, Sakai M, et al. The incidence of disseminated intravascular coagulation in dogs with malignant tumor. J Vet Med Sci 2004;66:573-575.
9. Wood CA, Moore AS, Gliatto JM, et al. Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991-1993). J Am Anim Hosp Assoc 1998;34:417-421.
10. Sorenmo K, Duda L, Barber L, et al. Canine hemangiosarcoma treated with standard chemotherapy and minocycline. J Vet Intern Med 2000;14:395-398.
11. Spangler WL, Kass PH. Pathologic factors affecting postsplenectomy survival in dogs. J Vet Intern Med 1997;11:166-171.
12. Clifford CA, Mackin AJ, Henry CJ. Treatment of canine hemangiosarcoma: 2000 and beyond. J Vet Intern Med 2000;14:479-485.
13. Ogilvie GK, Powers BE, Mallinckrodt CH, et al. Surgery and doxorubicin in dogs with hemangiosarcoma. J Vet Intern Med 1996;10:379-384.
14. Sorenmo KU, Baez JL, Clifford CA, et al. Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma. J Vet Intern Med 2004;18:209-213.
15. Vail DM, MacEwen EG, Kurzman ID, et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res 1995;1:1165-1170.
16. Dow SW, Fradkin LG, Liggitt DH, et al. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 1999;163:1552-1561.
17. Dow SW, Elmslie RE, Fradkin LG, et al. Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases. Hum Gene Ther 1999;10:2961-2972.
18. Higgins RJ, McKisic M, Dickinson PJ, et al. Growth inhibition of an orthotopic glioblastoma in immunocompetent mice by cationic lipid-DNA complexes. Cancer Immunol Immunother 2004;53:338-344.
19. Sellins K, Fradkin L, Liggitt D, et al. Type I interferons potently suppress gene expression following gene delivery using liposome(-)DNA complexes. Mol Ther 2005;12:451-459.
20. Dow S, Elmslie R, Kurzman I, et al. Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Hum Gene Ther 2005;16:937-946.
21. Kamstock D, Guth A, Elmslie R, et al. Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. Cancer Gene Ther 2006;13:306-317.
22. Zaks K, Jordan M, Guth A, et al. Efficient immunization and cross-priming with vaccine adjuvants containing TLR3 or TLR9 agonists complexed to liposomes. J Immunol 2006;176:7335-7345.
23. Mueller RS, Veir J, Fieseler KV, et al. Use of immunostimulatory liposome-nucleic acid complexes in allergen-specific immunotherapy of dogs with refractory atopic dermatitis - a pilot study. Vet Dermatol 2005;16:61-68.
24. Walter CU, Biller BJ, Lana SE, et al. Effects of chemotherapy on immune responses in dogs with cancer. J Vet Intern Med 2006;20:342-347.
25. Gursel M, Tunca S, Ozkan M, et al. Immunoadjuvant action of plasmid DNA in liposomes. Vaccine 1999;17:1376-1383.
26. Gregoriadis G, McCormack B, Obrenovic M, et al. Vaccine entrapment in liposomes. Methods 1999;19:156-162.
27. Dileo J, Banerjee R, Whitmore M, et al. Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses. Mol Ther 2003;7:640-648.
28. Thamm DH, Dickerson EB, Akhtar N, et al. Biological and molecular characterization of a canine hemangiosarcoma-derived cell line. Res Vet Sci 2006;81:76-86.
29. Templeton NS, Lasic DD, Frederik PM, et al. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 1997;15:647-652.
30. Veterinary Comparative Oncology Group, Veterinary comparative oncology group common terminology for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v 1.0. Vet Comp Oncol 2004;53:1-21.
31. Price GS, Page RL, Fischer BM, et al. Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma. J Vet Intern Med 1991;5:259-262.
32. Ogilvie GK, Richardson RC, Curtis CR, et al. Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors. J Am Vet Med Assoc 1989;195:1584-1587.
33. Mutsaers AJ, Glickman NW, DeNicola DB, et al. Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs. J Am Vet Med Assoc 2002;220:1813-1817.
34. Mitchell MS. Cancer vaccines, a critical review - Part I. Curr Opin Investig Drugs 2002;3:140-149.
35. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 2003;22:3188-3192.
36. Nemunaitis J. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev Vaccines 2005;4:259-274.
37. Bergman PJ, McKnight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003;9:1284-1290.
38. Alexander AN, Huelsmeyer MK, Mitzey A, et al. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunol Immunother 2005:1-10.
39. Gyorffy S, Rodriguez-Lecompte JC, Woods JP, et al. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. J Vet Intern Med 2005;19:56-63.
40. Labarthe MC, Halanek N, Birchall L, et al. The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model. Cancer Immunol Immunother 2006;55:277-288.
41. Pizza G, De Vinci C, Lo Conte G, et al. Allogeneic gene-modified tumour cells in metastatic kidney cancer. Report II. Folia Biol (Praha) 2004;50:175-183.
42. Sosman JA, Sondak VK. Melacine: an allogeneic melanoma tumor cell lysate vaccine. Expert Rev Vaccines 2003;2:353-368.
43. Sondak VK, Sosman JA. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. Semin Cancer Biol 2003;13:409-415.
44. Emens LA, Machiels JP, Reilly RT, et al. Chemotherapy: friend or foe to cancer vaccines? Curr Opin Mol Ther 2001;3:77-84.